tiagabine (gabitril) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Tiagabine (trade name Gabitril) is an anticonvulsant medication used in the treatment of Partial Seizures. The precise mechanism by which Tiagabine exerts its antiseizure effect is unknown, although it is believed to be related to its ability to enhance the activity of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. Tiagabine binds to recognition sites associated with the GABA uptake carrier. It is thought that, by this action, Tiagabine blocks GABA uptake into presynaptic neurons, permitting more GABA to be available for receptor binding on the surfaces of post-synaptic cells. Tiagabine is approved by U.S. Food and Drug Administration (FDA) as an adjunctive treatment for partial seizures in individuals of age 12 and up. It may also be prescribed off-label by physicians to treat anxiety disorders and panic disorder as well as neuropathic pain (including fibromyalgia). For anxiety and neuropathic pain, tiagabine is used primarily to augment other treatments. Tiagabine may be used alongside selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, or benzodiazepines for anxiety, or antidepressants, gabapentin, other anticonvulsants, or opioids for neuropathic pain. The most common side effect of tiagabine is dizziness. Other side effects that have been observed with a rate of statistical significance relative to placebo include asthenia, somnolence, nervousness, memory impairment, tremor, headache, diarrhea, and depression.   NCATS

Chemistry

  • SMILES: Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C
  • InChIKey: PBJUNZJWGZTSKL-MRXNPFEDSA-N
  • Mol. Mass: 375.56
  • ALogP: 5.04
  • ChEMBL Molecules:
    tiagabine  
    tiagabine hydrochloride  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.3790 - $1.0904

United States

$0.4127 - $14.6940
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

a-70569-1 | abbott-70569 | abbott-70569-1 | abbott-70569.1 | abbott-70569.hcl | abt-569 | gabatril | gabitril | n-(4,4-di(3-methylthien-2-yl)but-3-enyl)nipecotic acid | nnc-05-0328 | no-05-0328 | no 328 | no-328 | no 329 | no-329 | (r)-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid, hydrochloride | (r)-tiagabine | tiagabina | tiagabine | tiagabine hcl | tiagabine hydrochloride | tiagabine, (s)-isomer | tiagabinum | tigabine

Organizations (16)

Research & Development (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (2)


 

Epilepsies, Partial (approved 1997)

Seizures

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Alcoholism (Phase 1)

Anxiety (Phase 4)

Anxiety Disorders (Phase 3)

Cocaine-Related Disorders (Phase 2)

Epilepsies, Partial (Phase 4)

Opioid-Related Disorders (Phase 2)

Phobia, Social (Phase 4)

Schizophrenia (Phase 3)

Sexual Dysfunction, Physiological (Phase 4)

Sleep Apnea, Obstructive (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial Organizations: 12

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue